权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Optimizing Measures for Clinical Trials in Covert Hepatic Encephalopathy

隐性肝性脑病临床试验的优化措施

基本信息

批准号：
10132309
负责人：
Elliot Tapper
金额：
$ 19.4万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-07-01 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10132309
关键词：
Abdominal Muscles Address Adrenergic beta-Antagonists Adverse event Albumins American Ammonia Area Ascites Bilirubin Blood Brain Calibration Calories Catabolic Process Cessation of life Chronic Cirrhosis Clinical Clinical Trials Clinical Trials Design Code Coma Complication Computers Confusion Data Data Analyses Development Diagnosis Diet Dietary Intervention Disorientation Electronic Mail Enrollment Executive Dysfunction Exercise Exposure to Fall prevention Feasibility Studies Focus Groups Goals Gold Grant Hand Hemorrhage Hepatic Encephalopathy Hospitalization Inpatients Intervention Interview Investigation Knowledge Lethargies Malnutrition Master&apos s Degree Measures Mentorship Methodology Methods Modeling Muscle Muscle function Nutritional Online Systems Outcome Outpatients Pathway interactions Patient Outcomes Assessments Patient Selection Patients Personal Satisfaction Pharmaceutical Preparations Physical Function Portal Hypertension Positioning Attribute Prospective cohort Proteins Publishing Randomized Controlled Trials Research Research Personnel Retrospective cohort Risk Risk Factors Severities Structure Talents Testing Text Messaging Time Training Training Programs Voice Work abdominal CT arm authority base career chronic liver disease clinical investigation clinical predictors cognitive change cognitive function cohort cost daily functioning disability executive function exercise intervention falls grasp health care service utilization health related quality of life high risk improved inattention insight modifiable risk mortality neurocognitive test neuropsychiatry novel nutrition patient oriented point of care predictive modeling prevent prospective randomized trial resistance exercise response risk prediction risk stratification sarcopenia success therapeutic target therapy design tool vehicular accident wasting

项目摘要

Optimizing Measures for Clinical Trials in Covert Hepatic Encephalopathy PI: Elliot B. Tapper, MD Among all complications of cirrhosis, none is more devastating than hepatic encephalopathy (HE). Although it will afflict up to 40% of patients with cirrhosis, HE has few dedicated researchers. A spectrum of neuropsychiatric disability, HE ranges in severity from covert (deficits in executive function) to overt (confusion, even coma). Even covert HE – the earliest stage – is independently associated with repeated hospitalization, falls, motor vehicle accidents and death. Unfortunately, strategies to prevent the development HE are limited. Furthermore, investigations of potential therapies are complicated by limited knowledge of both the clinical predictors of HE and impact on patient well-being and daily functions. This grant proposes to close these gaps. The training program aims to prepare the applicant for a career vested in identifying risk factors for HE, and in designing interventions to prevent HE and to improve patient well-being. A master's degree in clinical investigation with targeted additional courses will provide training in clinical trial design, calibration of patient reported measures for clinical trials, and longitudinal data analysis to develop clinical predictive models. The mentorship team assembled is diverse and talented, including Dr. Anna Lok (a clinical trialist and content expert), Dr. Jasmohan Bajaj (an authority on HE and clinical trials), Dr. Noelle Carlozzi (a neuropsychologist with expertise in mixed-methodology), and Dr. Susan Murphy (a trialist with a focus on interventions for frail patients). In research aim 1, we will determine the most important domains of health related quality of life (HRQOL) for patients with covert HE. In Aim 2, we will analyze a cohort of 300 cirrhosis patients without HE followed for up to 4 years to determine the modifiable risk factors for HE and to develop predictive models for HE and falls. In Aim 3, we will launch a pilot intervention aimed at the improvement of HRQOL and prevention of falls in patients with covert HE using a web-based platform that co-ordinates a combination of text-message, email and interactive-voice response to deliver structured encouragement to meet nutritional and exercise goals aimed at improving sarcopenia. By the conclusion of the K23, the applicant will be positioned for academic success with a niche in an important complication of cirrhosis and providing necessary preliminary data for an R01 supporting a larger, randomized trial.

隐性肝性脑病临床试验的优化措施